• Maia Biotechnology reported strong enrollment momentum in THIO-104, a pivotal Phase 3 trial of ateganosine in third-line advanced non-small cell lung cancer.
• No new efficacy results were presented; the update focused on trial progress and timing for future readouts.
• 29 patients have been dosed across 34 active sites in six countries, with a target of up to 100 patients by year-end.
• An interim analysis is expected in 2027 once survival follow-up matures, setting the next key catalyst for the program.
• Ateganosine holds FDA Fast Track status, supporting a potentially accelerated development and regulatory path if Phase 3 data are positive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606040945PRIMZONEFULLFEED9731697) on June 04, 2026, and is solely responsible for the information contained therein.